Literature DB >> 20880698

Polymorphic variation in the androgen receptor gene: association with risk of testicular germ cell cancer and metastatic disease.

Åke Västermark1, Yvonne Lundberg Giwercman, Oskar Hagströmer, Ewa Rajpert De-Meyts, Jakob Eberhard, Olof Ståhl, Gabriella Cohn Cedermark, Hamideh Rastkhani, Gedske Daugaard, Stefan Arver, Aleksander Giwercman.   

Abstract

Increasing incidence of testicular germ cell cancer (TGCC) is most probably related to environment and lifestyle. However, an underlying genetic predisposition may play a role and since sex steroids are assumed to be important for the rise and progression of TGCC, a study of androgen receptor (AR) gene polymorphisms in relation to the risk, histological type and progression of TGCC was undertaken. In 367 TGCC cases and 214 controls, AR CAG and GGN repeat lengths were determined and 11 haplotype-tagging single nucleotide polymorphisms (SNPs) were genotyped. By binary logistic regression, odds ratios (ORs) and 95% confidence intervals (95% CI) were calculated for the risk of TGCC, non-seminoma versus seminoma and metastatic versus localised (stage I) disease. For the non-coding SNP, rs12014709, the minor genotype (G) was found in 10% of the cases and in 5.1% of the controls, conferring an OR of 2.07 (95% CI: 1.03-4.15) for having TGCC. Furthermore, short GGN (<23) was associated with an increased risk of metastatic disease (OR: 2.15; 95% CI: 1.04-4.45). The AR polymorphisms found by us might be involved in gene-environment interaction by increasing the susceptibility to the effect of endocrine disruptors. From a biological point of view, our findings strengthen the hypothesis of the importance of androgen action in the aetiology and pathogenesis of testicular malignancy. Future studies should focus on the impact of sex hormones on foetal germ cell development and the interaction between environmental factors and androgen receptor variants in relation to the risk of testicular malignancy.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20880698     DOI: 10.1016/j.ejca.2010.08.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

Review 1.  Testicular germ cell tumours: predisposition genes and the male germ cell niche.

Authors:  Duncan Gilbert; Elizabeth Rapley; Janet Shipley
Journal:  Nat Rev Cancer       Date:  2011-03-17       Impact factor: 60.716

2.  Heterogenous effect of androgen receptor CAG tract length on testicular germ cell tumor risk: shorter repeats associated with seminoma but not other histologic types.

Authors:  Carol A Davis-Dao; Kimberly D Siegmund; David J Vandenberg; Eila C Skinner; Gerhard A Coetzee; Duncan C Thomas; Malcolm C Pike; Victoria K Cortessis
Journal:  Carcinogenesis       Date:  2011-06-03       Impact factor: 4.944

3.  Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk.

Authors:  John Charles A Lacson; Joshua D Carroll; Ellenie Tuazon; Esteban J Castelao; Leslie Bernstein; Victoria K Cortessis
Journal:  Cancer       Date:  2012-09-10       Impact factor: 6.860

4.  Testicular cancer and cryptorchidism.

Authors:  Lydia Ferguson; Alexander I Agoulnik
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-20       Impact factor: 5.555

5.  Predictive value of GGN and CAG repeat polymorphisms of androgen receptors in testicular cancer: a meta-analysis.

Authors:  Weijun Jiang; Jing Zhang; Qing Zhou; Shuaimei Liu; Mengxia Ni; Peiran Zhu; Qiuyue Wu; Weiwei Li; Mingchao Zhang; Xinyi Xia
Journal:  Oncotarget       Date:  2016-03-22

Review 6.  Exploring the molecular aspects associated with testicular germ cell tumors: a review.

Authors:  Gaetano Facchini; Sabrina Rossetti; Carla Cavaliere; Carmine D'Aniello; Rossella Di Franco; Gelsomina Iovane; Giovanni Grimaldi; Raffaele Piscitelli; Paolo Muto; Gerardo Botti; Sisto Perdonà; Bianca Maria Veneziani; Massimiliano Berretta; Micaela Montanari
Journal:  Oncotarget       Date:  2017-11-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.